Nano-Selenium and the Src Family Kinases Pathway: Redefining Gene Expression Dynamics in Major Depressive Disorder Based on a Randomized Controlled Trial

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! By

Nano-Selenium and the Src Family Kinases Pathway: Redefining Gene Expression Dynamics in Major Depressive Disorder Based on a Randomized Controlled Trial Publisher

M Noormohammadi MORVARID ; F Etesam FARNAZ ; A Amini ALI ; P Khosravian PEGAH ; M Mohamadzade MORTEZA ; F Shidfar FARZAD

Source: Current Journal of Neurology Published:2024

Abstract

Background: Major depressive disorder (MDD) is a prevalent psychiatric condition. Dysregulation of signaling pathways interacting with SRC family kinases has been implicated in the pathophysiology of MDD through inflammation. Nano-selenium, a nanoscale form of selenium with enhanced bioavailability, has the potential to modulate oxidative stress and inflammation, which are implicated in MDD. To the best of our knowledge, in this study, for the first time we aimed to examine whether nano-selenium supplementation would decrease c-SRC gene expression. Methods: This triple-blind, randomized, placebo-controlled clinical trial was conducted at Imam Khomeini Hospital Complex, Tehran, Iran. © 2025 Elsevier B.V., All rights reserved.

Related Docs

View other Related Docs

1. Impact of Nano-Selenium Supplementation on the Jak/Stat Signaling Pathway in Major Depressive Disorder: A Triple-Blind, Randomized Controlled Trial, BMC Psychiatry (2025)

2. The Rationale for Selenium Supplementation in Inflammatory Bowel Disease: A Mechanism-Based Point of View, Nutrition (2021)

3. The Effects of Dietary Selenium Supplementation on Inflammatory Markers Among Patients With Metabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Journal of Diabetes and Metabolic Disorders (2021)

Experts (# of related papers)

View all Related Experts

Shahin Akhondzadeh Basti (2)

Amir Hossein Emami (1)

Other Related Docs

4. Evaluation of Nanocurcumin Effects on Depressive-Like Behaviors in Rats and Determination of Serum Bdnf and Serotonin Levels, Brain and Behavior (2025)

5. The Effect of Selenium Therapy in Critically Ill Patients: An Umbrella Review of Systematic Reviews and Meta-Analysis of Randomized Controlled Trials, European Journal of Medical Research (2023)

6. Antioxidant Effects of Selenium in Adult Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Topics in Clinical Nutrition (2023)

7. Neuroprotective Effects of Cerium Oxide Nanoparticles on Experimental Stress-Induced Depression in Male Rats, Journal of Chemical Neuroanatomy (2020)

8. The Effects of Selenium Supplementation on Lipid Profile and the Inflammatory and Oxidative Stress Markers in Patients With Kidney Diseases: A Systematic Review and Meta-Analysis, Topics in Clinical Nutrition (2025)

9. Selenium Supplementation and Oxidative Stress: A Review, PharmaNutrition (2021)

10. Efficacy and Safety of Celecoxib Monotherapy for Mild to Moderate Depression in Patients With Colorectal Cancer: A Randomized Double-Blind, Placebo Controlled Trial, Psychiatry Research (2017)

11. Celecoxib in Treatment of Postpartum Depression: A Case Report, Archives of Iranian Medicine (2023)

Style	Citing Format
MLA	M Noormohammadi MORVARID, et al.. "Nano-Selenium and the Src Family Kinases Pathway: Redefining Gene Expression Dynamics in Major Depressive Disorder Based on a Randomized Controlled Trial." Current Journal of Neurology, vol. 23, no. 4, 2024, pp. 240-250.
APA	M Noormohammadi MORVARID, F Etesam FARNAZ, A Amini ALI, P Khosravian PEGAH, M Mohamadzade MORTEZA, F Shidfar FARZAD (2024). Nano-Selenium and the Src Family Kinases Pathway: Redefining Gene Expression Dynamics in Major Depressive Disorder Based on a Randomized Controlled Trial. Current Journal of Neurology, 23(4), 240-250.
Chicago	M Noormohammadi MORVARID, F Etesam FARNAZ, A Amini ALI, P Khosravian PEGAH, M Mohamadzade MORTEZA, F Shidfar FARZAD. "Nano-Selenium and the Src Family Kinases Pathway: Redefining Gene Expression Dynamics in Major Depressive Disorder Based on a Randomized Controlled Trial." Current Journal of Neurology 23, no. 4 (2024): 240-250.
Harvard	M Noormohammadi MORVARID et al. (2024) 'Nano-Selenium and the Src Family Kinases Pathway: Redefining Gene Expression Dynamics in Major Depressive Disorder Based on a Randomized Controlled Trial', Current Journal of Neurology, 23(4), pp. 240-250.
Vancouver	M Noormohammadi MORVARID, F Etesam FARNAZ, A Amini ALI, P Khosravian PEGAH, M Mohamadzade MORTEZA, F Shidfar FARZAD. Nano-Selenium and the Src Family Kinases Pathway: Redefining Gene Expression Dynamics in Major Depressive Disorder Based on a Randomized Controlled Trial. Current Journal of Neurology. 2024;23(4):240-250.
BibTex	@article{ author = {M Noormohammadi MORVARID and F Etesam FARNAZ and A Amini ALI and P Khosravian PEGAH and M Mohamadzade MORTEZA and F Shidfar FARZAD}, title = {Nano-Selenium and the Src Family Kinases Pathway: Redefining Gene Expression Dynamics in Major Depressive Disorder Based on a Randomized Controlled Trial}, journal = {Current Journal of Neurology}, volume = {23}, number = {4}, pages = {240-250}, year = {2024} }
RIS	TY - JOUR AU - M Noormohammadi MORVARID AU - F Etesam FARNAZ AU - A Amini ALI AU - P Khosravian PEGAH AU - M Mohamadzade MORTEZA AU - F Shidfar FARZAD TI - Nano-Selenium and the Src Family Kinases Pathway: Redefining Gene Expression Dynamics in Major Depressive Disorder Based on a Randomized Controlled Trial JO - Current Journal of Neurology VL - 23 IS - 4 SP - 240 EP - 250 PY - 2024 ER -

Science Communicator Platform

Authors

Abstract